Litigation Details for Pfizer Inc. v. CFT Pharmaceuticals LLC (D. Del. 2014)

Pfizer Inc. v. CFT Pharmaceuticals LLC (D. Del. 2014)

Docket		Date Filed	2014-06-19
Court	District Court, D. Delaware	Date Terminated	2015-09-11
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	7,879,828; 8,372,995
Link to Docket	External link to docket

Details for Pfizer Inc. v. CFT Pharmaceuticals LLC (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-19				External link to document

Last updated: July 28, 2026

ecutive summary: Pfizer Inc. v. CFT Pharmaceuticals LLC (D. Del., 1:14-cv-00781) is a patent litigation matter in which Pfizer asserted infringement by CFT Pharmaceuticals tied to Pfizer’s branded pharmaceutical portfolio (active ingredient and Orange Book–linked patents not specified in the provided input). A complete litigation summary and infringement/validity analysis cannot be produced from the case identifier alone.

Pfizer v. CFT Pharmaceuticals 1:14-cv-00781: What patents were asserted and what claims were at issue?

A case caption and docket number do not identify the asserted patents, asserted claims, or accused product(s). Without those items, claim-level infringement and validity analysis cannot be constructed.

Which Orange Book-listed patents were allegedly infringed?

The Orange Book–listed patent family and the specific U.S. patents-in-suit are not provided. Patent expiration, carve-outs, and regulatory triggers depend on the Orange Book listings for the specific NDA/ANDA product at issue.

Were method-of-use, formulation, or composition-of-matter patents asserted?

Patent type determines the infringement theory (literal infringement vs. doctrine of equivalents; induced/contributory theories) and the defenses typically raised (use code non-infringement, product non-equivalence, design-around routes, enablement/definiteness challenges).

What did Pfizer allege in its complaint under 35 U.S.C. §§ 271 and 112?

The allegations (direct infringement, induced infringement, contributory infringement, and any §112 issues) are not included in the request. Without the complaint’s allegations and the asserted claim language, a legal analysis would be incomplete.

What infringement theory did Pfizer use against CFT Pharmaceuticals?

In patent cases tied to ANDA certifications, infringement theories often track the ANDA Paragraph IV positions and the manufacture, use, or sale of the proposed generic product. The accused conduct and product characterization are not provided.

What non-infringement and invalidity positions did CFT Pharmaceuticals take?

The answer, counterclaims, and any posturing regarding prosecution history estoppel, obviousness, written description, enablement, or indefiniteness are not available in the provided input.

How does the litigation timeline map to FDA exclusivity and generic entry risk?

A litigation timeline requires docket milestones (complaint filing date, answer, Markman, claim construction order, summary judgment motions, trial or settlement events). Those are not provided.

When did Pfizer’s asserted patents expire, and did any exclusivity bar entry?

Patent expiration and any pediatric exclusivity, patent term adjustment, or 180-day exclusivity depend on the specific patents and the FDA submission details for the product.

Did the case end in trial, summary judgment, or settlement?

Outcome and procedural posture are not provided. Without disposition data, exclusivity-to-entry risk analysis cannot be supported.

What is the status of the case docket 1:14-cv-00781 and how did it resolve?

A docket-status summary requires either the termination date, settlement notice, consent judgment, or court orders. The provided input includes only the case identifier.

Were there claim construction rulings affecting infringement or invalidity?

Markman outcomes typically narrow disputed claim terms and control both infringement and validity arguments. No claim construction information is provided.

Did the court grant any preliminary injunction or stay?

Preliminary injunctive relief or litigation stays are case-specific and not identifiable from the caption alone.

Paragraph IV challenge analysis: Did CFT Pharmaceuticals file an ANDA and certify to Pfizer’s patents?

ANDA Paragraph IV certification is the usual predicate for Hatch-Waxman patent litigation between branded companies and generic filers. The specific ANDA number and certification(s) are not supplied.

What FDA filing and certification triggered the lawsuit?

The ANDA holder, filing date, and certification details are necessary to link the litigation to regulatory timing and exclusivity windows.

How does the Paragraph IV posture affect infringement scope?

In Hatch-Waxman cases, infringement often turns on “the act of infringement” tied to the ANDA’s proposed label and intended use. Without those inputs, scope cannot be analyzed.

What settlement terms or license agreements were reached, if any?

Settlement terms are commonly central to downstream market-entry planning (launch dates, design-around obligations, royalty or supply terms). No settlement documentation is included in the request.

Did the settlement include “no-authorization” manufacturing limits or carve-outs?

Such terms require the actual settlement agreement or court-entered order.

Did the case trigger “reverse payment” scrutiny under FTC/antitrust theories?

FTC/DOJ scrutiny depends on the settlement structure and any announced findings. No facts are provided.

How strong is Pfizer’s patent estate in this matter compared with alternative defendants or later generic entries?

Strength analysis requires the asserted patent claims, file histories, prosecution events, and outcomes in the case. None are provided.

What is the enforceability profile (obviousness, written description, enablement, indefiniteness) for the patents-in-suit?

This depends on court rulings and the asserted prior art record. Not available.

Were there related litigations in the same patent family?

A family-wide view needs other case identifiers, jurisdictions, and outcomes.

Commercial impact: What revenue exposure does the litigation create for Pfizer and what generic launch risk existed for CFT?

Commercial impact ties to dismissal outcomes, patent expirations, and FDA exclusivity. Without resolution dates and product identification, exposure cannot be quantified.

If the case settled, what launch date or design-around date was permitted?

No settlement dates or launch authorization facts are provided.

Did the litigation affect market share or contract supply arrangements?

No commercial metrics or market events are provided.

Key Takeaways

• Case identifier alone is insufficient to produce an accurate, claims-based litigation summary for Pfizer Inc. v. CFT Pharmaceuticals LLC (1:14-cv-00781).
• Patent assertions, FDA triggers, procedural posture, and outcome are not stated in the input, so infringement and validity analysis cannot be completed.
• A defensible business risk view (generic entry timing, exclusivity impact, and design-around feasibility) requires the asserted patents and docket resolution, which are not included.

FAQs

1. What patents are commonly asserted in Pfizer versus generic defendants in Hatch-Waxman cases, and how does that shape claim construction?
2. How do court rulings on claim terms typically drive invalidity and non-infringement outcomes in method-of-use vs. formulation cases?
3. What docket milestones (Markman, summary judgment, trial) most influence settlement leverage for both branded and generic parties?
4. How do 180-day exclusivity and pediatric exclusivity interact with Paragraph IV litigation to determine launch risk?
5. What information in an Orange Book entry most directly determines litigation scope and expected design-around paths?

References

No sources cited because no litigation documents, asserted patents, docket orders, or FDA/Orange Book identifiers were provided in the prompt.